Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation

Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation

The Von-Hippel-Lindau (VHL) gene, acting as a tumor suppressor, plays a crucial role in the tumorigenesis of clear cell renal cell carcinoma (ccRCC). Approximately 90% of individuals with advanced ccRCC exhibit somatic mutations in the VHL gene. Belzutifan, orally administered small-molecule inhibit...

Full description

Bibliographic Details
Main Authors: Kok Hoe Chan MD, Ningjing Li MD, Ran Lador MD, Mark Amsbaugh MD, Anneliese Gonzalez MD, Putao Cen MD
Format: Article
Language:English
Published: SAGE Publishing 2024-02-01
Series:Journal of Investigative Medicine High Impact Case Reports
Online Access:https://doi.org/10.1177/23247096241231641

Internet

https://doi.org/10.1177/23247096241231641

Similar Items